{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:15:24Z","timestamp":1789704924151,"version":"4.0.1"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"CACMS Innovation Fund","award":["CI2021A00917"],"award-info":[{"award-number":["CI2021A00917"]}]},{"name":"Fundamental Research Funds for the Central public welfare research institutes","award":["ZZ13-YQ-002"],"award-info":[{"award-number":["ZZ13-YQ-002"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Treatment of heart failure with preserved ejection fraction (HFpEF) is urgently needed; however, effective treatments are lacking. Current evidence showed a possible association between the use of calcium channel blockers (CCBs) and improved outcomes in HFpEF patients. We aimed to investigate the impact of CCBs on mortality in patients with HFpEF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>This was a post hoc analysis of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial. The primary outcome was all-cause mortality. The secondary outcomes were cardiovascular and noncardiovascular mortality. We analysed hazard ratios (HRs) in patients taking CCBs compared with those not taking CCBs using Cox proportional hazard models. We considered 3440 HFpEF patients. The mean follow-up period was 3.4 \u00b1 1.7 years, and 530 patients died during the study period. All-cause mortality rates in patients taking and not taking CCB were 37.3 and 50.8 events per 1000 person-years, respectively. The adjusted HR for all-cause mortality was significantly lower in those taking CCBs than those not taking CCBs [HR: 0.72, 95% confidence interval (CI): 0.59\u20130.88, P = 0.001]. The risk of cardiovascular and noncardiovascular mortality was also significantly lower in patients taking CCBs than in those not taking CCBs (HR: 0.75, 95% CI: 0.59\u20130.96, P = 0.023 and HR: 0.68, 95% CI: 0.49\u20130.93, P = 0.018, respectively).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The use of CCBs was associated with reduced risks of mortality in patients with HFpEF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurjpc\/zwac004","type":"journal-article","created":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T20:14:53Z","timestamp":1641413693000},"page":"1343-1351","source":"Crossref","is-referenced-by-count":14,"title":["Associations between calcium channel blocker therapy and mortality in heart failure with preserved ejection fraction"],"prefix":"10.1093","volume":"29","author":[{"given":"Xinyi","family":"Wang","sequence":"first","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences , No. 1 XiYuan CaoChang, Haidian District , Beijing 100091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqing","family":"Ju","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences , No. 1 XiYuan CaoChang, Haidian District , Beijing 100091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuo","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences , No. 1 XiYuan CaoChang, Haidian District , Beijing 100091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Lin","sequence":"additional","affiliation":[{"name":"CCU, Beijing Changping Hospital of Integrated Chinese and Western Medicine , No. 219 Huangping Road, Changping District, Beijing 102208 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine , No. 11 Bei San Huan Dong Lu, Chaoyang District, Beijing 100029 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyi","family":"Li","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine , No. 11 Bei San Huan Dong Lu, Chaoyang District, Beijing 100029 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[{"name":"Graduate School, Beijing University of Chinese Medicine , No. 11 Bei San Huan Dong Lu, Chaoyang District, Beijing 100029 , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9484-9819","authenticated-orcid":false,"given":"Hao","family":"Xu","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences , No. 1 XiYuan CaoChang, Haidian District , Beijing 100091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keji","family":"Chen","sequence":"additional","affiliation":[{"name":"National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences , No. 1 XiYuan CaoChang, Haidian District , Beijing 100091, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,7]]},"reference":[{"key":"2022072021484713300_zwac004-B1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","article-title":"Epidemiology of heart failure with preserved ejection fraction","volume":"14","author":"Dunlay","year":"2017","journal-title":"Nat Rev Cardiol"},{"key":"2022072021484713300_zwac004-B2","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.jacc.2017.08.074","article-title":"Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes","volume":"70","author":"Shah","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022072021484713300_zwac004-B3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"key":"2022072021484713300_zwac004-B4","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2022072021484713300_zwac004-B5","doi-asserted-by":"crossref","first-page":"e213651","DOI":"10.1001\/jamacardio.2021.3651","article-title":"Potential implications of expanded US Food and Drug Administration labeling for sacubitril\/valsartan in the US","volume":"6","author":"Vaduganathan","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2022072021484713300_zwac004-B6","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/ejhf.813","article-title":"Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, midrange and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry","volume":"19","author":"Chioncel","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022072021484713300_zwac004-B7","first-page":"e391","article-title":"2009 focused update incorporated into the ACC\/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation","volume":"119","author":"Hunt","year":"2009","journal-title":"Circulation"},{"key":"2022072021484713300_zwac004-B8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ijcard.2013.12.008","article-title":"Prognostic factors of heart failure with preserved ejection fraction: a 12-year prospective cohort follow-up study","volume":"171","author":"Wu","year":"2014","journal-title":"Int J Cardiol"},{"key":"2022072021484713300_zwac004-B9","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","article-title":"Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction","volume":"7","author":"Patel","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2022072021484713300_zwac004-B10","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2022072021484713300_zwac004-B11","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","article-title":"Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction","volume":"162","author":"Desai","year":"2011","journal-title":"Am Heart J"},{"key":"2022072021484713300_zwac004-B12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1161\/CIRCHEARTFAILURE.112.972794","article-title":"Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial","volume":"6","author":"Shah","year":"2013","journal-title":"Circ Heart Fail"},{"key":"2022072021484713300_zwac004-B13","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards regression model","volume":"69","author":"Schoenfeld","year":"1982","journal-title":"Biometrika"},{"key":"2022072021484713300_zwac004-B14","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1001\/jama.2015.13480","article-title":"The propensity score","volume":"314","author":"Haukoos","year":"2015","journal-title":"JAMA"},{"key":"2022072021484713300_zwac004-B15","year":"2021"},{"key":"2022072021484713300_zwac004-B16","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1056\/NEJMcp1511175","article-title":"Heart failure with preserved ejection fraction","volume":"375","author":"Redfield","year":"2016","journal-title":"N Engl J Med"},{"key":"2022072021484713300_zwac004-B17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/18.suppl_A.87","article-title":"Left ventricular dysfunction: which role for calcium antagonists?","volume":"18","author":"Iliceto","year":"1997","journal-title":"Eur Heart J"},{"key":"2022072021484713300_zwac004-B18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/eurheartj\/ehs299","article-title":"Effect of antihypertensive therapy on ventricular-arterial mechanics, coupling, and efficiency","volume":"34","author":"Lam","year":"2013","journal-title":"Eur Heart J"},{"key":"2022072021484713300_zwac004-B19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.lfs.2007.11.010","article-title":"T-type Ca2+ channel blockers prevent ardiac cell hypertrophy through an inhibition of calcineurin-NFAT3 activation as well as L-type Ca2+ channel blockers","volume":"82","author":"Horiba","year":"2008","journal-title":"Life Sci"},{"key":"2022072021484713300_zwac004-B20","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1097\/HJH.0b013e3283281254","article-title":"Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients","volume":"27","author":"Costanzo","year":"2009","journal-title":"J Hypertens"},{"key":"2022072021484713300_zwac004-B21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9149(00)01413-2","article-title":"Meta-analysis of efficacy and safety of second-generation dihydropyridine calcium channel blockers in heart failure","volume":"87","author":"Cleophas","year":"2001","journal-title":"Am J Cardiol"},{"key":"2022072021484713300_zwac004-B22","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/HJH.0000000000000848","article-title":"Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure\u2014meta-analyses of randomized trials","volume":"34","author":"Thomopoulos","year":"2016","journal-title":"J Hypertens"},{"key":"2022072021484713300_zwac004-B23","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1146\/annurev-med-041316-090654","article-title":"Heart failure with preserved ejection fraction","volume":"69","author":"Gladden","year":"2018","journal-title":"Annu Rev Med"},{"key":"2022072021484713300_zwac004-B24","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1097\/HJH.0000000000002910","article-title":"Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension","volume":"39","author":"Kasiakogias","year":"2021","journal-title":"J Hypertens"},{"key":"2022072021484713300_zwac004-B25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/10641963.2016.1267198","article-title":"Azelnidipine is a useful medication for the treatment of heart failure preserved ejection fraction","volume":"39","author":"Kiuchi","year":"2017","journal-title":"Clin Exp Hypertens"},{"key":"2022072021484713300_zwac004-B26","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0735-1097(01)01548-0","article-title":"Long-term administration of amlodipine prevents decompensation to diastolic heart failure in hypertensive rats","volume":"38","author":"Nishikawa","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"2022072021484713300_zwac004-B27","first-page":"17","article-title":"Calcium channel blockers: differences between subclasses","author":"Frishman","year":"2007","journal-title":"Am J Cardiovasc Drugs"},{"key":"2022072021484713300_zwac004-B28","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5603\/CJ.2020.0023","article-title":"Coding proposal on phenotyping heart failure with preserved ejection fraction: a practical tool for facilitating etiology-oriented therapy","volume":"27","author":"Ge","year":"2020","journal-title":"Cardiol J"},{"key":"2022072021484713300_zwac004-B29","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.jacc.2015.03.043","article-title":"Patient selection in heart failure with preserved ejection fraction clinical trials","volume":"65","author":"Kelly","year":"2015","journal-title":"J Am Coll Cardiol"}],"container-title":["European Journal of Preventive Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurjpc\/advance-article-pdf\/doi\/10.1093\/eurjpc\/zwac004\/42237369\/zwac004.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/9\/1343\/45032530\/zwac004.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurjpc\/article-pdf\/29\/9\/1343\/45032530\/zwac004.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T21:49:47Z","timestamp":1658353787000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurjpc\/article\/29\/9\/1343\/6500314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,7]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,1,7]]},"published-print":{"date-parts":[[2022,7,20]]}},"URL":"https:\/\/doi.org\/10.1093\/eurjpc\/zwac004","relation":{},"ISSN":["2047-4873","2047-4881"],"issn-type":[{"value":"2047-4873","type":"print"},{"value":"2047-4881","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,1,7]]}}}